Close
Solutions
Online Inquiry
Global Services

T Cell-mediated Tumor Cell Lysis Assay

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Leveraging Creative Biolabs' extensive team of experts and advanced technology platforms, we offer T cell-mediated tumor cell lysis assays to help you validate the targeted effectiveness of your CAR-T products.

Background Our Service WorkflowHighlights FAQs

Background

Due to the diversity and complexity of CAR-T products, reproducible and reliable methods for validating anti-tumor activity are needed for further product development. Effector cells, including cytotoxic T cells (CTLs), can induce apoptosis through cell-to-cell contact, eliminating target cells. Creative Biolabs offers two different assays to quantify the cytolytic activity of T cells against target tumor cells.

Fig.1 Cytotoxic T cells induce damage to target cells. (Bettina, 2022) Fig.1 Cytotoxic T cells induce damage to target cells.¹

Our Service

Scope of Our Service Basic Principle Our Aim Our Guarantee
One-stop CAR-T service from basic research to clinical trials Specific recognition of engineered T cell receptors expressing neoantigens on tumor cells To evaluate the targeted tumor killing efficacy of different CAR-T products
  • Ensure that CAR-T cell products contain functional CAR-T cells with targeted tumor-killing activity
  • Evaluate samples provided by customers

Creative Biolabs offers two assays to measure T cell-mediated tumor cell lysis:

  • Radiolabeling assay

This method involves incubating target tumor cells with radiolabels, which promote the binding of specific radiolabels to cytosolic proteins. When the target tumor cell is recognized by the CAR-T cell, the target tumor cell is killed, releasing the radiolabel.

  • In vitro live-cell assay
    This method is to use in vitro live-cell assays to verify the anti-tumor activity of CAR-T cells. Unlike radiolabels, this assay uses specific fluorescent cytoplasmic reagents to label target tumor cells to measure tumor cell lysis through real-time imaging and monitoring of live cells. Advantages of this assay:
    • Cells are safe at optimal concentrations of specific fluorescent cytoplasmic reagents;
    • Accurately used for short-term experiments;
    • The ratio of target tumor cells to CAR-T cells can be optimized;

Workflow

The following is a basic workflow diagram of our T cell-mediated tumor cell lysis assay. Creative Biolabs has been committed to bringing high-quality products and services to our customers. Through detailed upfront research and close communication, we are confident in offering an appropriate assay format to meet your exact project requirements.

Fig.2 Assay flow of T cell-mediated tumor cell lysis. (Creative Biolabs Original) Fig.2 Assay flow of T cell-mediated tumor cell lysis.

Highlights

Fig.3 Highlights of our service. (Creative Biolabs Original) Fig.3 Highlights of our service.

Frequently Asked Questions

Q1: How do we move the project forward?

A: If you have a complete protocol or a clear assay process, you can get in touch with one of our experts directly for a quote. If your project is still in the exploration stage, you can contact us without hesitation, and our professional experts can conduct research and customize a customized plan for your project.

Q2: What will Creative Biolabs deliver to customers at the end of the project?

A: When the project is over, you will receive all the raw data as well as a detailed analysis report (if required). Of course, we will also keep in touch with you during the project.

Based on years of continuous research and exploration in the field of CAR, Creative Biolabs has launched the One-Stop CAR-T Therapy Development service, covering the design and construction of CAR to the testing of the effectiveness of CAR products in vitro and in vivo. If you are interested in the field of CAR and looking for help, you can always get in touch with us. The experts of Creative Biolabs are always online to help you.

Reference

  1. Bettina.W.; et al. "T cell-mediated additive cytotoxicity – death by multiple bullets." Trends in Cancer. (2022).
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.